Incurix
PrivateLast Round
Grant
Dec 7, 2023
Company Overview
Incurix is a drug discovery company that develops anticancer drugs designed for targeting tumor transcription factors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Incurix Comparables
Compare Incurix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MycRx | 87% | |
| WebenPharma | 84% | |
| Peptomyc | 78% | |
Incurix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 7, 2023 | ||||
| Grant | Sep 22, 2023 | ||||
| Series A | Mar 1, 2021 |
Incurix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Korea Drug Development Fund | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 7, 2023
Received grant funding from the Korea Drug Development Fund.
- Sep 22, 2023
Received grant funding from Korea Drug Development Fund.
Incurix Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Incurix's valuation, stock price, and market status.